SYNTEX TORADOL IM SYRINGE FAILURE REPORTS ARE SUBJECT OF FDA WARNING
Executive Summary
SYNTEX TORADOL IM SYRINGE FAILURE REPORTS ARE SUBJECT OF FDA WARNING letter sent to the company March 4. During an inspection of Syntex' Palo Alto facilities in October and November, the warning letter states, an FDA inspector "discussed with your staff complaints FDA had received from health care professionals concerning defects in the delivery system" for Toradol (ketorolac) injectable. "Chief among the complaints was the failure of the prefilled syringe plunger to fully depress, resulting in only a portion of the drug dosage being delivered to the patient," the letter states.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth